Nonselective phosphodiesterase inhibitor; xanthine derivative

This page covers all Nonselective phosphodiesterase inhibitor; xanthine derivative drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Phosphodiesterase enzymes (nonselective); adenosine receptors (antagonist), Phosphodiesterase (non-selective), Phosphodiesterase.

Targets

Phosphodiesterase enzymes (nonselective); adenosine receptors (antagonist) · Phosphodiesterase (non-selective) · Phosphodiesterase · Non-selective phosphodiesterase inhibitor; multiple targets including adenosine receptors · Glucocorticoid receptor; phosphodiesterase (non-selective)

Marketed (3)

• Theophylline Anhydrous Oral Tablet · Damanhour Teaching Hospital · Respiratory/Pulmonology
  Theophylline is a nonselective phosphodiesterase inhibitor that increases intracellular cAMP and cGMP, producing bronchodilation and anti-inflammatory effects.
• pentoxifylline (drug) · National Taiwan University Hospital · Cardiovascular / Vascular disease
  Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.
• Pentoxifylline sustained-release tablets · Beijing Tiantan Hospital · Cardiovascular
  Pentoxifylline improves blood flow and reduces inflammation by inhibiting phosphodiesterase enzymes and modulating cytokine production.

Phase 3 pipeline (4)

• pentoxyphylline (PTX) · National Taiwan University Hospital · Cardiovascular
  Pentoxyphylline (PTX) is a methylxanthine derivative that acts as a phosphodiesterase inhibitor, increasing cyclic AMP levels and improving blood flow.
• MED2005 · Futura Medical Developments Ltd. · Urology / Sexual Health
  MED2005 is a topical cream formulation designed to enhance erectile function through local application to penile tissue.
• Placebo to Pentoxifylline oral · UCB Pharma · Cardiovascular / Vascular disease
  Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.
• Corticosteroid or pentoxifylline · Saint Vincent's Hospital, Korea · Immunology / Inflammatory disease
  This combination therapy uses corticosteroids to suppress inflammatory immune responses and pentoxifylline to improve blood flow and reduce inflammatory cytokine production.

Phase 2 pipeline (2)

• EHT 0202 etazolate · Exonhit · Neurology
  Etazolate is a phosphodiesterase inhibitor.
• Defibrotide Injection · IRCCS San Raffaele · Oncology
  Phosphodiesterase inhibitor

Patent intelligence

• phosphodiesterase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates